Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: SDHB Gene Mutation Clear all

Active, not recruiting Phase 2 Interventional

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

NCT06087263

View directory record Official record

Conditions: Gastrointestinal Stromal Tumors
Interventions: Regorafenib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jan 19, 2026 · Synced May 22, 2026, 1:35 AM EDT

Completed Phase 2 Interventional Results available

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

NCT01967576

View directory record Official record

Conditions: Pheochromocytoma, Paraganglioma
Interventions: Axitinib (AG-013736); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years

Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Jan 5, 2021 · Synced May 22, 2026, 1:35 AM EDT

Recruiting Phase 2 Interventional

PH 2 Pemigatinib in SDH-deficient GIST

NCT07434843

View directory record Official record

Conditions: SDH Gene Mutation, Gastrointestinal Stromal Tumor
Interventions: Pemigatinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Apr 20, 2026 · Synced May 22, 2026, 1:35 AM EDT

Recruiting No phase listed Observational Accepts healthy volunteers

MyVHL: Patient Natural History Study

NCT03749980

View directory record Official record

Conditions: Von Hippel-Lindau Disease, Hereditary Leiomyomatosis and Renal Cell Cancer, Birt-Hogg-Dube Syndrome, SDHB Gene Mutation
Interventions: Not listed
Lead sponsor: Joshua Mann, MPH; Other
Eligibility: Not listed

Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Apr 25, 2024 · Synced May 22, 2026, 1:35 AM EDT